JP2018500385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500385A5 JP2018500385A5 JP2017544555A JP2017544555A JP2018500385A5 JP 2018500385 A5 JP2018500385 A5 JP 2018500385A5 JP 2017544555 A JP2017544555 A JP 2017544555A JP 2017544555 A JP2017544555 A JP 2017544555A JP 2018500385 A5 JP2018500385 A5 JP 2018500385A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence identity
- pain
- conotoxin peptide
- item
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 108050003126 conotoxin Proteins 0.000 claims description 44
- 208000002193 Pain Diseases 0.000 claims description 30
- 230000036407 pain Effects 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- JBZXBEBRZLKCGN-BYPYZUCNSA-N (2s)-2-(2-diazohydrazinyl)pentanoic acid Chemical compound CCC[C@@H](C(O)=O)NN=[N+]=[N-] JBZXBEBRZLKCGN-BYPYZUCNSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims description 2
- 201000007954 uterine fibroid Diseases 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 6
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
- 150000004665 fatty acids Chemical group 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091058551 α-conotoxin Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462123123P | 2014-11-07 | 2014-11-07 | |
| US62/123,123 | 2014-11-07 | ||
| PCT/US2015/059613 WO2016073949A1 (en) | 2014-11-07 | 2015-11-06 | Modifications and uses of conotoxin peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040876A Division JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500385A JP2018500385A (ja) | 2018-01-11 |
| JP2018500385A5 true JP2018500385A5 (OSRAM) | 2018-12-13 |
| JP6798998B2 JP6798998B2 (ja) | 2020-12-09 |
Family
ID=55909927
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544555A Active JP6798998B2 (ja) | 2014-11-07 | 2015-11-06 | コノトキシンペプチドの修飾および使用 |
| JP2020040876A Withdrawn JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
| JP2022010036A Pending JP2022063872A (ja) | 2014-11-07 | 2022-01-26 | コノトキシンペプチドの修飾および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040876A Withdrawn JP2020090550A (ja) | 2014-11-07 | 2020-03-10 | コノトキシンペプチドの修飾および使用 |
| JP2022010036A Pending JP2022063872A (ja) | 2014-11-07 | 2022-01-26 | コノトキシンペプチドの修飾および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11014970B2 (OSRAM) |
| EP (1) | EP3215172B1 (OSRAM) |
| JP (3) | JP6798998B2 (OSRAM) |
| KR (1) | KR102623475B1 (OSRAM) |
| CN (1) | CN107249616A (OSRAM) |
| AU (2) | AU2015342767B2 (OSRAM) |
| CA (1) | CA2966865C (OSRAM) |
| ES (1) | ES2950901T3 (OSRAM) |
| HK (1) | HK1244201A1 (OSRAM) |
| IL (2) | IL284236B2 (OSRAM) |
| TW (2) | TWI708790B (OSRAM) |
| WO (1) | WO2016073949A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107249616A (zh) | 2014-11-07 | 2017-10-13 | 奇尼塔慢性疼痛有限责任公司 | 芋螺毒素(conotoxin)肽的修饰和用途 |
| RU2731217C2 (ru) * | 2016-11-28 | 2020-08-31 | Общество с ограниченной ответственностью "Синейро" | Аналог альфа-конотоксина RgIA для лечения боли |
| US10947274B1 (en) * | 2018-05-01 | 2021-03-16 | University Of Utah Research Foundation | Synthetic analgesic peptides of RgIA analogs |
| KR102117106B1 (ko) | 2018-09-14 | 2020-06-01 | 대한민국(환경부 국립생물자원관장) | N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| CR20210363A (es) * | 2019-01-04 | 2021-12-10 | Kineta Chronic Pain Llc | Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias |
| CN115702161A (zh) * | 2020-04-09 | 2023-02-14 | 格罗制药公司 | 抑制烟碱乙酰胆碱受体活性的肽组合物和方法 |
| WO2021247936A1 (en) * | 2020-06-03 | 2021-12-09 | University Of Utah Research Foundation | CONFORMATIONALLY-CONSTRAINED α- -RGIA ANALOGUES |
| CN114805492B (zh) * | 2022-03-15 | 2025-07-22 | 上海元炘执药科技有限公司 | 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用 |
| CN115286700B (zh) * | 2022-08-22 | 2024-11-19 | 中国海洋大学 | 一种具有血浆稳定性的镇痛多肽 |
| CN118184744A (zh) * | 2024-03-29 | 2024-06-14 | 广西大学 | 一种靶向神经型乙酰胆碱受体的多肽分子及其制备方法和应用 |
| CN119912549A (zh) * | 2024-12-29 | 2025-05-02 | 中国人民解放军军事科学院防化研究院 | 一类脂肪醛修饰的芋螺肽及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595972A (en) | 1993-06-29 | 1997-01-21 | University Of Utah Research Foundation | Conotoxin peptides |
| US6797808B1 (en) | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
| TR200201036T2 (tr) * | 1999-10-18 | 2002-08-21 | Akzo Nobel N.V. | İmmünoterapide kullanmak için değiştirilmiş peptitler ve peptido-taklitleri |
| WO2004050688A1 (en) | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP1770099A1 (en) * | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| US7745573B2 (en) * | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| CA2566832A1 (en) * | 2006-04-13 | 2007-10-13 | The University Of Queensland | Cyclised alpha-conotoxin peptides |
| US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| CA2663083A1 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| US20090326192A1 (en) * | 2008-04-08 | 2009-12-31 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| DE102009050885A1 (de) * | 2009-10-27 | 2011-04-28 | Behr Gmbh & Co. Kg | Luftausströmer |
| CN105377286B (zh) * | 2013-05-31 | 2021-07-02 | 犹他大学研究基金会 | 芋螺毒素(conotoxin)肽，其医药组合物和用途 |
| CN107249616A (zh) | 2014-11-07 | 2017-10-13 | 奇尼塔慢性疼痛有限责任公司 | 芋螺毒素(conotoxin)肽的修饰和用途 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
-
2015
- 2015-11-06 CN CN201580068468.7A patent/CN107249616A/zh active Pending
- 2015-11-06 JP JP2017544555A patent/JP6798998B2/ja active Active
- 2015-11-06 CA CA2966865A patent/CA2966865C/en active Active
- 2015-11-06 IL IL284236A patent/IL284236B2/en unknown
- 2015-11-06 TW TW104136722A patent/TWI708790B/zh not_active IP Right Cessation
- 2015-11-06 US US15/525,024 patent/US11014970B2/en active Active
- 2015-11-06 TW TW109134130A patent/TWI777260B/zh not_active IP Right Cessation
- 2015-11-06 EP EP15856496.3A patent/EP3215172B1/en active Active
- 2015-11-06 AU AU2015342767A patent/AU2015342767B2/en active Active
- 2015-11-06 ES ES15856496T patent/ES2950901T3/es active Active
- 2015-11-06 HK HK18103429.5A patent/HK1244201A1/zh unknown
- 2015-11-06 WO PCT/US2015/059613 patent/WO2016073949A1/en not_active Ceased
- 2015-11-06 KR KR1020177015279A patent/KR102623475B1/ko active Active
-
2017
- 2017-05-07 IL IL252152A patent/IL252152B/en unknown
-
2020
- 2020-03-10 JP JP2020040876A patent/JP2020090550A/ja not_active Withdrawn
- 2020-09-29 US US17/037,521 patent/US11618772B2/en active Active
-
2021
- 2021-08-03 AU AU2021212006A patent/AU2021212006B2/en active Active
-
2022
- 2022-01-26 JP JP2022010036A patent/JP2022063872A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500385A5 (OSRAM) | ||
| TWI708790B (zh) | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 | |
| JP2011511753A5 (OSRAM) | ||
| TW202140513A (zh) | 人類運鐵蛋白受體結合肽 | |
| JP2022551153A (ja) | 活性ポリペプチド化合物 | |
| US20240139279A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2023512587A (ja) | Ｐａｎｘ１関連疾患の治療 | |
| US20170246311A1 (en) | Peptides for binding alternatively activated macrophages | |
| EP2909226A1 (en) | Derivatives of collagen-binding hairpin peptides | |
| JP6615504B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| CA2581110A1 (en) | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions | |
| JP2005060315A (ja) | 製剤組成物 | |
| ES3040184T3 (en) | Fusion protein preparation comprising il-2 and cd80 proteins | |
| JP6831128B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| CA2943802C (en) | Cyclic prosaposin peptides and uses thereof | |
| RU2021115678A (ru) | Конъюгаты интерлейкина 10 и варианты их применения | |
| HK40090948A (en) | Cyclic prosaposin peptides and uses thereof | |
| Huang | Biomimicry: Exploring Peptoids and Recombinant Protein Polymers for Biomedical Applications | |
| NZ741870B2 (en) | Integrin binding peptides and uses thereof | |
| HK1233930B (en) | Cyclic prosaposin peptides and uses thereof | |
| HK1233930A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| NZ741870A (en) | Integrin binding peptides and uses thereof |